Iconic KCK burger drive-in reopens under new ownership
Paul's Jr. Drive-in is under new ownership but still serves the same menu. It's grand opening was last week but people decided to wait out the long line Wednesday on National Burger Day.
Storm chaser shares memories of 2019 Linwood tornado
'I came down here the other day, and the line was way back there, and now it's National Burger Day , so I'm going to go try it out,' said customer Vaughn Taylor.
It's got a slightly different name, but the establishment still holds the same memories.
'My mom used to bring us down here. She's no longer here, but it's one of her favorite spots,' Taylor said.
'I came down with my parents when we were kids at that time we had to share a basket,' customer Frances Ferguson said. '[Now] I got the adult money, they're going to share a basket this time.'
Stories customers get to relive again, thanks to Daniel Macias, the new owner.
'I grew up with the original owners, they were friends of the family, so I used to go to the back door and help them out,' he said.
He knows the original owners, Harry and Mary Smith, would be proud. Harry died several years ago, Mary died last week.
'I wanted her to be here to make the grand opening and unfortunately she wasn't able to but she was able to see the videos from the week before when we did our soft opening and that was just as crazy,' Macias said.
After waiting years to see if it'll reopen, waiting in these lines for a bite, customers say it's worth it to support a staple in the community.
'I had my nephew come down and he stood in line for four hours, he stood in line for four hours,' Ferguson said.
While there are some small changes, Macias said the menu is the same. Satisfying customers' cravings with a side of nostalgia.
Download WDAF+ for Roku, Fire TV, Apple TV
'Thank you for all the love and support you guys are truly a blessing,' Macias said.
Paul's Jr. Drive-in is located at 1008 S. Osage Avenue in KCK's Armoudale neighborhood. It's open 10 a.m. to 8 p.m. every day except Sundays.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
22 minutes ago
- The Hill
In-N-Out isn't coming to these states anytime soon
(KTLA) — In-N-Out Burger's expansion into Tennessee gained new attention this week when CEO Lynsi Snyder announced on a podcast that she is moving her family from California to the Volunteer State. However, buried within the interview was a comment that will certainly disappoint fans of the fast-food giant across a wide swath of the U.S. In-N-Out isn't coming to the East Coast anytime soon. 'Florida has begged us, and we're still saying no,' Snyder, 43, told Allie Beth Stuckey, host of the faith-focused podcast Relatable. 'The [other] East Coast states—we're still saying no.' The Southern California-based chain announced its Tennessee expansion in January 2023, with a regional office in Franklin, a suburb of Nashville, slated to open next year. According to the Nashville Business Journal, the burger giant is eyeing 35 potential locations in Tennessee, which will be served by the company's distribution center in Lancaster, Texas. In-N-Out is known for using only fresh ingredients — never frozen — including ground beef, so its stores are generally located within 500 miles of its distribution centers. 'We're not putting a whole meat facility where we do all our own beef [in Tennessee]. We'll have a warehouse, but not do our own meat there,' Snyder said. She added that other states within range of the Lancaster facility could also be part of the burger chain's expansion plans — likely leaving In-N-Out fans in Oklahoma, Arkansas, Louisiana, Kansas, Mississippi, and Missouri salivating over the possibility of Double-Doubles and Animal Fries in their future. Lynsi, the granddaughter of In-N-Out founders Harry and Esther Snyder, said the company needs to approach growth with a focus on quality over quantity. 'We have to have some growth, but we also don't want to be on every corner. We don't want to be in every state, and we don't want to ever compromise our values and standards—the cornerstones that my grandparents laid down,' she said. In-N-Out currently operates over 400 stores in eight states: California, Texas, Arizona, Nevada, Utah, Colorado, Oregon and Idaho. Its first Washington state location is expected to open within the next several weeks.
Business Wire
22 minutes ago
- Business Wire
Pathward Secures a Spot on the 2025 Monitor 100
SIOUX FALLS, S.D.--(BUSINESS WIRE)--Pathward Financial, Inc. (Nasdaq: CASH) through its subsidiary, Pathward®, N.A. ('bank' or 'Pathward'), announced that it has earned a spot on the 2025 Monitor 100 list. Monitor, a magazine focused on equipment finance, publishes the annual Monitor 100 rankings to recognize and celebrate the top equipment finance and leasing organizations across the nation based on portfolio activity and volume of business each year. The 2025 Monitor 100 list looks at company performance in 2024. 'We're honored to be recognized on the Monitor 100 list for the 13th year in a row,' said Christopher Soupal, Divisional President and Revenue Lending Officer at Pathward. 'Being named to the annual list of top equipment finance companies is a testament to our team that is dedicated to Pathward's purpose of financial inclusion and providing funding solutions to help businesses reach their goals.' Read Pathward's feature on page 28 in the Monitor 100 2025 | Vol. 52 No. 4. In addition to Equipment Finance solutions, Pathward offers Working Capital and Structured Finance solutions as part of our forward-thinking Commercial Finance portfolio. Learn more about our flexible finance capabilities and options for a broad range of industries on our website at About Pathward Financial, Inc. Pathward Financial, Inc. (Nasdaq: CASH) is a U.S.-based financial holding company driven by its purpose to power financial inclusion. Through our subsidiary, Pathward®, N.A., we strive to increase financial availability, choice and opportunity across our Partner Solutions and Commercial Finance business lines. These strategic business lines provide support to individuals and businesses. Learn more at About Pathward® Pathward®, N.A., a national bank, is a subsidiary of Pathward Financial, Inc. (Nasdaq: CASH). Pathward is focused on financial access and strives to increase financial availability, choice and opportunity across our Partner Solutions and Commercial Finance business lines. The strategic business lines provide support to individuals and businesses. Learn more at
Business Wire
22 minutes ago
- Business Wire
Aditxt's Subsidiary Pearsanta Receives an Invitation to Submit Full Proposal for the U.S. Department of Defense Pilot Award for the Development of its Mitomic® Ovarian Test
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, is pleased to announce that its subsidiary, Pearsanta, Inc. (' Pearsanta'), has received an invitation to submit a full proposal for the Congressionally Directed Medical Research Program's (CDMRP) Ovarian Cancer Research Program ('OCRP') Pilot Award, funded through the U.S. Department of Defense (Funding Opportunity Number: HT942525OCRPPA) for its Mitomic® Ovarian Test ('MOT™'), a novel blood-based diagnostic for ovarian cancer. Pearsanta's Mitomic® technology is a platform that is designed to use mitochondrial DNA to identify biomarkers and to develop tests for early detection of cancer and other diseases. Pearsanta is currently conducting clinical validation of the first two tests that have been developed based on this technology for early detection of prostate cancer and endometriosis. MOT™ will potentially be another blood-based test to be added to the Company's product pipeline designed for earlier detection of ovarian cancer. Ovarian cancer currently has a poor prognosis due to the fact that it is typically detected in later stages. Early detection of ovarian cancer can potentially improve the outcomes for women who face this terrible disease. Pearsanta submitted a pre-proposal on June 10, 2025, which was favorably reviewed for its scientific merit, level of innovation, alignment with OCRP Areas of Interest, and potential impact. The full proposal, titled 'Mitochondrial DNA Deletions in Plasma as a Diagnostic Aid for Ovarian Cancer,' is currently under development and will be submitted by the September 11, 2025, deadline. The OCRP Pilot Award offers up to $350,000 over two years to support high-risk, high-reward research that could lead to critical discoveries and advance the field of ovarian cancer diagnostics and treatment. Pearsanta's proposed project aligns directly with the program's priority to 'identify and develop new strategies for screening, early-stage detection, accurate diagnosis, and prognosis.' 'Early detection is one of the greatest unmet needs in ovarian cancer care,' said Chris Mitton, President of Pearsanta. 'Our Mitomic® Ovarian Test has the potential to enable timely, more effective interventions, improve survival rates, and ultimately save lives. If successful, it could change the standard of care by offering a simple blood test that detects ovarian cancer at an earlier, more treatable stage—potentially improving survival and quality of life for women.' The study aims to further develop and validate the MOT™ at Pearsanta's Richmond, Virginia CLIA/CAP laboratory and monitoring facility in preparation for commercial launch as a laboratory-developed test (LDT). Plans include a prospective, multi-center clinical study to collect and analyze blood samples from women undergoing evaluation for suspected ovarian cancer. 'Pearsanta's continued progress is a powerful validation of our mission to accelerate promising health innovations with real-world impact,' said Amro Albanna, CEO of Aditxt. 'We believe the Mitomic® platform has the potential to transform how diseases are detected and managed. Supporting the development of the MOT™ reflects our broader strategy to Acquire high-potential innovations, Build them into clinically and commercially viable solutions, and Capitalize their value to drive scalable deployment globally. About Pearsanta Pearsanta is at the forefront of precision health, focusing on early cancer detection through advanced diagnostic technologies. Its proprietary Mitomic Technology Platform leverages the unique properties of mitochondrial DNA to detect cancer and other diseases with high accuracy via non-invasive, blood-based liquid, biopsy tests. Pearsanta's asset portfolio also includes a range of other innovative diagnostic technologies, all aimed at transforming early disease detection and monitoring, enabling more informed treatment decisions and ultimately improving patient outcomes. For more information, please visit About Aditxt, Inc. Aditxt, Inc. is a social innovation platform accelerating promising health innovations. Aditxt's ecosystem of research institutions, industry partners, and shareholders collaboratively drives their mission to "Make Promising Innovations Possible Together." The innovation platform is the cornerstone of Aditxt's strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder's voice is heard and valued, and empowers collective progress. The Company currently operates two programs focused on immune health, and precision health. Through the proposed acquisition of Evofem under the July 2024 Amended and Restated Merger Agreement between Evofem, Aditxt and Adifem, Inc., as amended (the "A&R Merger Agreement"), Aditxt aims to introduce an additional program dedicated to women's health. The companies are working toward a targeted close in the second half of 2025. The closing of the transaction with Evofem is subject to several conditions, including but not limited to approval of the transaction by Evofem's shareholders and Aditxt raising sufficient capital to fund its obligations at closing. These obligations include cash payments of approximately $17 million for Evofem, which includes approximately $15.0 million required to satisfy Evofem's senior secured noteholder; should Aditxt fail to secure these funds, Evofem's senior secured noteholder is expected to seek to prevent the closing of the merger with Evofem. No assurance can be provided that all of the conditions to closing will be obtained or satisfied, or that the transaction will ultimately close. Forward-Looking Statements This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "achieving," "advancing", "aim," "are working to," "believe," "completing," "continue," "could," "design," "estimate," "expect," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "seek," "should," "suggest," "strategy," "target," "will," "would," and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include but are not limited to the potential success of Pearsanta's proposal for the U.S. Department of Defense Pilot Award; the ability of Pearsanta's Mitomic technology, including the MOT, to detect cancer or other diseases; Pearsanta's ability to commence in-human clinical trials on the proposed timeline, if at all; Aditxt's ability to successfully execute its mission to accelerate and monetize promising health innovations, and magnitude thereof; Aditxt's ability to complete the proposed initial public offering of Pearsanta on the proposed timeline, if at all; and Aditxt's ability to close the planned acquisition of Evofem, including to meet all closing conditions, and the timing thereof. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements are disclosed in each company's SEC filings, including Aditxt's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 31, 2025, and any subsequent Form 10-Q filings. All forward-looking statements are expressly qualified in their entirety by such factors. Aditxt undertakes no duty to update any forward-looking statement except as required by law. For more information, please visit Follow Aditxt on:
